Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALTA-2350
- Development stage
- Unknown
- Lead developer
- Sumitovant Biopharma
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Inhalation
01
Overview
**ALTA-2350** is a novel inhaled formulation of recombinant interleukin-1 receptor antagonist (IL-1Ra), a protein therapeutic designed to inhibit the pro-inflammatory cytokine interleukin-1 (IL-1) by competitively binding to its receptor. Developed for potential use in inflammatory respiratory conditions, it leverages inhalation for targeted lung delivery to block IL-1 mediated inflammation, which drives tissue damage in diseases like acute lung injury or pulmonary fibrosis. Sumitovant Biopharma is advancing it through early nonclinical proof-of-concept studies as of late 2022, highlighting its potential as a localized anti-inflammatory therapy.[9]
02
Targets
IL1R1 (Interleukin-1 Receptor Type 1)IL-1R (Interleukin-1 receptor type 1 (IL-1R1))
Beyond the preview
Go deeper on ALTA-2350.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALTA-2350.